Filing Analysis
Century Therapeutics announced that Bristol-Myers Squibb (BMS) is terminating its Research, Collaboration and License Agreement without cause. The termination will be effective March 12, 2025.
🚩 Red Flags
- Loss of a major strategic partner (Bristol-Myers Squibb) in the biotech sector.
- Termination follows an 'internal corporate portfolio prioritization process' by BMS, suggesting a shift in their strategic focus away from Century's specific programs.
- The company is undergoing a 'strategic review' of its pre-clinical pipeline.
📋 Key Facts
- BMS notified the Company on December 12, 2024, of the termination of the Collaboration Agreement.
- The agreement was originally entered into on January 7, 2022.
- Termination is 'without cause' and will be effective March 12, 2025.
- The collaboration focused on iPSC-derived engineered natural killer cell and gamma delta T cell programs for hematologic malignancies.
Century Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2024 and provided an updated investor presentation.
📋 Key Facts
- Reported financial results for the quarter ended September 30, 2024 via press release (Exhibit 99.1).
- Issued an updated slide presentation for investor meetings (Exhibit 99.2).
- The company is classified as an 'emerging growth company'.
Century Therapeutics, Inc. announced the appointment of Morgan Conn, Ph.D., as its new Chief Financial Officer and principal financial officer, effective October 14, 2024.
📋 Key Facts
- Morgan Conn, Ph.D. to join as CFO effective October 14, 2024.
- Annual base salary set at $470,000 with a 40% target annual performance bonus.
- One-time signing bonus of $100,000.
- Equity compensation includes an option for 360,890 shares and RSU award for 60,148 shares.
- Dr. Conn previously served as Chief Business Officer at Pharvaris N.V. and held leadership roles at PTC Therapeutics.
Century Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided an updated investor presentation.
📋 Key Facts
- Report date: August 8, 2024
- Financial results announced for the quarter ended June 30, 2024 (Item 2.02)
- Updated investor slide presentation provided via Regulation FD disclosure (Item 7.01)
Century Therapeutics, Inc. filed an 8-K to update its investor presentation materials. The company intends to use the updated slides in upcoming meetings with investors.
📋 Key Facts
- The filing was made on July 8, 2024.
- The primary purpose is to provide an updated slide presentation (Exhibit 99.1).
- The company intends to use the updated presentation for investor relations meetings.
Century Therapeutics, Inc. filed an amendment to its April 11, 2024, 8-K to provide required financial statements and pro forma information following its acquisition of Clade Therapeutics, Inc.
🚩 Red Flags
- The filing is an amendment to provide missing required financial information from a previous acquisition announcement.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to the original report filed on April 11, 2024.
- Century Therapeutics acquired Clade Therapeutics, Inc. effective April 11, 2024.
- Includes audited financial statements of Clade for the year ended December 31, 2023 (Exhibit 99.1).
- Includes unaudited pro forma condensed combined financial statements as of December 31, 2023 (Exhibit 99.2).
Century Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The meeting included the election of three Class III directors and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on June 20, 2024.
- Elected Kimberly Blackwell, M.D., Joseph Jimenez, and Brent Pfeiffenberger, Pharm.D. to the Board of Directors (Class III) until 2027.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024.
- Approved an amendment to the Certificate of Incorporation to limit officer liability per Delaware law.
- Record date for meeting was April 24, 2024, with 82,847,375 shares outstanding.
Century Therapeutics issued an 8-K to announce a poster presentation of interim Phase 1 ELiSE-1 study results for CNTY-101 at the ASCO Annual Meeting. The company also updated its investor slide presentation.
📋 Key Facts
- Announced interim results from the ongoing Phase 1 ELiPSE-1 study evaluating CNTY-101 in relapsed or refractory non-Hodgkin lymphoma.
- Presentation occurred at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).
- Updated investor slide presentation provided as Exhibit 99.2.
Century Therapeutics, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing was made on May 9, 2024.
- Reporting period: Quarter ended March 31, 2024.
- The company is an emerging growth company.
- Financial results were released via a press release (Exhibit 99.1).
Century Therapeutics announced a dual-track capital event: a $60 million private placement of common stock and the acquisition of Clade Therapeutics. The company is simultaneously raising significant cash to fund clinical expansion while executing an M&A transaction.
🚩 Red Flags
- Significant dilution: The issuance of ~15.8M shares at $3.78 represents a major equity event for a micro-cap/small-cap biotech.
- Liquidated damages clause in the Registration Rights Agreement (1% per 30 days) is a punitive term often demanded by aggressive institutional investors.
📋 Key Facts
- Private Placement: Issuance of 15,873,011 shares at $3.78 per share to institutional accredited investors.
- Gross proceeds from private placement expected to be approximately $60 million.
- Acquisition of Clade Therapeutics for an upfront consideration of ~$35 million ($15M cash + 4,535,333 shares).
- Potential clinical development milestone payment of up to $10 million for the Clade acquisition.
- Registration Rights Agreement requires filing a registration statement within 30 days of closing; includes 1% liquidated damages per 30-day period if deadlines are missed.
- BofA Securities acted as sole placement agent.
Century Therapeutics, Inc. filed an 8-K to update its investor presentation materials. The company intends to use the updated slide deck in upcoming meetings with investors.
📋 Key Facts
- The filing was made on April 11, 2024.
- The primary purpose is to provide an updated investor presentation (Exhibit 99.1).
- The company is classified as an 'emerging growth company'.
Century Therapeutics, Inc. issued an 8-K to announce the presentation of preclinical data from its iPSC-derived cell therapy platform at the AACR Annual Meeting 2024.
📋 Key Facts
- The company presented preclinical data regarding its iPSC-derived cell therapy platform on April 8, 2024.
- Data presentation focused on end-to-end capabilities including iPSC reprogramming, differentiation, gene editing, synthetic biology, protein engineering, and computational biology.
- The announcement was made via a press release filed as Exhibit 99.1.
Century Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided an updated investor presentation.
📋 Key Facts
- Announced full-year 2023 financial results via press release (Exhibit 99.1).
- Updated investor slide presentation for use in upcoming meetings with investors (Exhibit 99.2).
- Filed as an emerging growth company.
Century Therapeutics announced the resignation of its Chief Financial Officer, Michael C. Diem, M.D., effective February 2, 2024. The company has appointed Douglas Carr as interim Principal Financial Officer while searching for a permanent replacement.
🚩 Red Flags
- Unexpected departure of a key C-suite executive (CFO).
📋 Key Facts
- Michael C. Diem, M.D. resigned as CFO on January 15, 2024.
- Resignation becomes effective February 2, 2024.
- Douglas Carr (SVP, Finance and Operations) appointed as interim Principal Financial Officer.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.